Recombinant Human UMPS protein

中文名： 尿苷单磷酸合成酶(UMPS)重组蛋白
别名： UMPS；Uridine 5'-monophosphate synthase

货号: PA1000-3415

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	UMPS
Uniprot No	P11172
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-480aa
氨基酸序列	MGSSHHHHHH SSGLVPRGSH MAVARAALGP LVTGLYDVQA FKFGDFVLKS GLSSPIYIDL RGIVSRPRLL SQVADILFQT AQNAGISFDT VCGVPYTALP LATVICSTNQ IPMLIRRKET KDYGTKRLVE GTINPGETCL IIEDVVTSGS SVLETVEVLQ KEGLKVTDAI VLLDREQGGK DKLQAHGIRL HSVCTLSKML EILEQQKKVD AETVGRVKRF IQENVFVAAN HNGSPLSIKE APKELSFGAR AELPRIHPVA SKLLRLMQKK ETNLCLSADV SLARELLQLA DALGPSICML KTHVDILNDF TLDVMKELIT LAKCHEFLIF EDRKFADIGN TVKKQYEGGI FKIASWADLV NAHVVPGSGV VKGLQEVGLP LHRGCLLIAE MSSTGSLATG DYTRAAVRMA EEHSEFVVGF ISGSRVSMKP EFLHLTPGVQ LEAGGDNLGQ QYNSPQEVIG KRGSDIIIVG RGIISAADRL EAAEMYRKAA WEAYLSRLGV
预测分子量	54 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于UMPS重组蛋白的3篇参考文献示例(基于真实研究领域，但具体内容为概括性描述)：

---

1. **文献名称**: *Expression and characterization of recombinant human UMP synthase*

**作者**: Poon, R., & Davidson, A. G.

**摘要**: 该研究报道了人源UMPS基因在大肠杆菌中的重组表达及纯化，分析了重组蛋白的酶动力学特性，证实其双功能活性(乳清酸磷酸核糖转移酶和乳清酸核苷酸脱羧酶)，为核苷酸代谢研究提供了工具。

2. **文献名称**: *Structural insights into the catalytic mechanism of UMP synthase*

**作者**: Li, H., et al.

**摘要**: 通过X射线晶体学解析了重组UMPS蛋白的三维结构，揭示了其底物结合位点和催化机制，为设计靶向UMPS的抑制剂(如抗肿瘤药物)提供了结构基础。

3. **文献名称**: *Role of UMP synthase in 5-fluorouracil resistance: Analysis using recombinant protein variants*

**作者**: Zhang, Y., et al.

**摘要**: 研究通过构建UMPS突变体重组蛋白，发现特定氨基酸残基突变可导致5-FU代谢异常，阐明了肿瘤细胞对5-FU耐药性与UMPS活性变化的关联。

---

**注**：上述文献为领域典型研究方向示例，实际引用时建议通过PubMed或Web of Science检索最新具体文献(关键词：UMPS, recombinant expression, 5-FU resistance)。

背景信息

UMPS (Uridine Monophosphate Synthase) is a bifunctional enzyme critical in the de novo pyrimidine biosynthesis pathway, which is essential for DNA and RNA synthesis. It catalyzes the last two steps of converting orotate to uridine monophosphate (UMP), a precursor for all pyrimidine nucleotides. The enzyme comprises two distinct catalytic domains: orotate phosphoribosyltransferase (OPRTase), which transfers a phosphoribosyl group to orotate, and orotidine-5'-monophosphate decarboxylase (ODCase), which decarboxylates the intermediate to form UMP. This dual functionality makes UMPS a key regulatory point in nucleotide metabolism.

Recombinant UMPS proteins are engineered using genetic cloning techniques, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., yeast or mammalian cells). Their production enables detailed biochemical studies, including enzyme kinetics, substrate specificity, and inhibition mechanisms. Recombinant UMPS has become particularly valuable in drug discovery, as pyrimidine biosynthesis is a target for anticancer and antimicrobial therapies. For instance, inhibitors like 5-fluorouracil act through UMPS-related pathways to disrupt rapidly dividing cells.

Clinically, UMPS deficiencies are linked to hereditary orotic aciduria, a rare metabolic disorder. Recombinant UMPS aids in developing enzyme replacement strategies and diagnostic tools for such conditions. Structural analyses of recombinant UMPS using X-ray crystallography have revealed conformational changes during catalysis, informing the design of allosteric modulators. Additionally, its role in activating prodrugs (e.g., 5-fluorouracil to active metabolites) underscores its importance in pharmacogenomics research.

Overall, recombinant UMPS serves as a vital tool for understanding pyrimidine metabolism, advancing therapeutic interventions, and optimizing treatment protocols for diseases involving nucleotide imbalance.